Skip to main content
SpringerLink
Log in

Pharmacokinetics of daunorubicin and daunorubicinol in plasma, P388 and B16 tumours. Comparison with in vitro cytotoxicity data

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The comparison of pharmacokinetics of DNR in mouse plasma, in theDNR naturally resistant B16 melanoma and in theDNR naturally sensitive P388 leukemia showed that there is no direct correlation between total concentrations of this drug in tumours and the sensitivity resistance of these tissues.

A finding which demonstrates the inadequacy of distribution models to select new potential anticancer drugs. Cytotoxicity of DNR and its metabolites to B16 melanoma and P388 leukemia cell lines were determined in vitro. Calculated inhibitory concentrations SO (IC50) were compared to maximal concentrations determined by pharmacokinetic studies.

In all cases in vitro IC50 were lower than Cmax values. Moreover, resistant cells in vivo were found to be sensitive to DNR and metabolites when they are propagated in vitro.

Tissue concentrations, as well as in vitro data, were fitted to appropriate models by an original program (FADHA) which uses the simplex method to minimize a non-linear cost function. Best fit models were chosen by statistical criteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dubois J., Hanocq M., Atassi G. (1987): Determination of Doxorubicin, Daunorubicin and some of their metabolites in mouse plasma by high-performance reversed-phase liquid chromatography with amperometric detection. Anal. Lett., 20, 1611–1634.

    CAS  Google Scholar 

  2. Dubois J., Hanocq M., Atassi G. (1987): Extraction and assay of daunorubicin and its metabolites from neoplastic tissue. Int. J. Pharm., 35, 219–276.

    Article  CAS  Google Scholar 

  3. Abi Khalil F., Dubois J., Hanocq M., Atassi G. (1986): A new algorithm for computing the parameters of linear compartment models in pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet., 11, 51–59.

    Article  CAS  Google Scholar 

  4. Dubois J., Abi Khalil F., Hanocq M., Atassi G., Arnould R. (1989): Ajustement des courbes dose-effet au moyen d’un algorithme original. Application à des études de cytotoxicité in vitro. J. Pharm. Belg., 44, 181–191.

    CAS  PubMed  Google Scholar 

  5. Arnould R. Dubois J., Abi Khalil F., et al. (1989): Comparison of two cytotoxicity assays — tetrazolium derivative reduction (MTT) and tritiated thymidine uptake — on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res., 9, 6.

    Google Scholar 

  6. Ritschel W.A. (1982): Handbook of Basic Pharmacokinetics, 2nd edn. Hamilton, Drug Intelligence Publications Inc.

    Google Scholar 

  7. Laird A. (1965): Dynamics of tumour growth: comparison of growth rates and extrapolation of growth curve to one cell. Br. J. Cancer, 19, 278–291.

    CAS  PubMed  Google Scholar 

  8. Silliman R. (1969): Comparison between Gompertz and Von Bertalanffy curves for expressing growth in weight of fishes. J. Fish Res. Bd. Can., 26, 161–165.

    Google Scholar 

  9. Akaïke H. (1974): A new look at the statistical model identification IEEE Trans. Autom. Contr, AC 19, 716–723.

    Article  Google Scholar 

  10. Schwarz G. (1978): Estimating the dimension of a model. Ann. Stat., 6, 461–464.

    Article  Google Scholar 

  11. Imbimbo B.P., Imbimbo E., Daniotti S., Verotha D., Bassotti G. (1988): A new criterion for selection of pharmacokinetic multiexponential equations. J. Pharm. Sci., 77, 784–789.

    Article  CAS  PubMed  Google Scholar 

  12. Norman H. (1975): Statistical Package for the Social Sciences. McGraw-Hill.

  13. Speth P., Van Hoesel A., Hoanen C. (1988): Clinical pharmacokinetics of Doxorubicin. 15, 15–31.

    Article  CAS  Google Scholar 

  14. NCI data: Personal information from Dr G. Atassi.

  15. Arnould R., Dubois J., Abi Khalil F., et al. (1990): Compared cytotoxicity effects of five anticancer drugs on human (HBL) and mouse B16 melanoma cells in vitro. Anticancer Res., 1, 3.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de Toxicologie et de Chimie bioanalytique, Université Libre de Bruxelles, Institut de Pharmacie, Bd. du Triomphe, CP 205/1, B-1050, Bruxelles, Belgium

    J. Dubois, M. Hanocq & F. Abikhalil

  2. Laboratoire de Pharmacologie Cellulaire, Université Libre de Bruxelles, Institut de Pharmacie, Bruxelles, Belgium

    G. Atassi

  3. LOCE, Université Libre de Bruxelles, Institut Bordet, Bruxelles, Belgium

    R. Arnould

Authors
  1. J. Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Hanocq
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Atassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Arnould
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Abikhalil
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dubois, J., Hanocq, M., Atassi, G. et al. Pharmacokinetics of daunorubicin and daunorubicinol in plasma, P388 and B16 tumours. Comparison with in vitro cytotoxicity data. European Journal of Drug Metabolism and Pharmacokinetics 16, 119–127 (1991). https://doi.org/10.1007/BF03189948

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189948

Keywords

Search

Navigation